Document Detail


Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection.
MedLine Citation:
PMID:  15607364     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several studies have investigated the influence of clinical and biological variables on mobilisation of peripheral blood progenitor cells (PBPCs). The aim of this study was to evaluate the role of steady-state bone marrow (BM) CD34+ cells as a predictive parameter of PBPC yield. We studied 90 patients with multiple myeloma (MM) (41 patients), non-Hodgkin's lymphoma (NHL) (25 patients) or acute myeloid leukaemia (AML) (24 patients), mobilised with chemotherapy and growth factor. The median time from first treatment to mobilisation was 5 months. Only one patient was previously exposed to alkylating agents. The median BM CD34+ count at mobilisation was 833 microl(-1) (range: 1.4-15.540) corresponding to 1.51% of mononuclear cells (range: 0.02-8.6). Sixty-six patients (73%) reached the optimal target of 4 x 10(6) kg(-1) CD34+ cells with 1 (18 patients), 2 (42 patients) or 3 leukaphereses (6 patients). Eleven patients (12%) mobilised less than 4 x 10(6) kg(-1) CD34+ cells and 13 (15%) failed mobilisation. Among the laboratory and clinical parameters evaluated at the time of mobilisation, only BM CD34+ count was a predictive factor for adequate collection (P = 0.04), particularly in MM patients (P = 0.003). In this setting, a BM concentration of CD34+ cells lower than 66 microL(-1) was associated with a higher probability of inadequate collection.
Authors:
Alessandro Corso; Marzia Varettoni; Silvia Mangiacavalli; Patrizia Zappasodi; Catherine Klersy; Chiara Rusconi; Emile Colucci; Angela Lorenzi; Daniela Troletti; Erica Consensi; Mario Lazzarino
Related Documents :
7448824 - Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemi...
17245764 - Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelog...
53444 - A clinical service for prenatal diagnosis.
9251314 - Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
16901564 - D-dimer local expression is increased in symptomatic patients undergoing carotid endart...
23899114 - Is daytime blood pressure adequate in cardiovascular risk assessment in patients with c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia research     Volume:  29     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2004-12-20     Completed Date:  2005-02-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  159-63     Citation Subset:  IM    
Affiliation:
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy. a.corso@smatteo.pv.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antigens, CD34 / analysis,  biosynthesis*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  pharmacology
Blood Cell Count*
Bone Marrow Cells / cytology*,  drug effects,  physiology
Female
Filgrastim / adverse effects,  pharmacology
Hematopoietic Stem Cell Mobilization / methods*
Hematopoietic Stem Cells / cytology*,  drug effects
Humans
Leukemia, Myeloid, Acute / blood,  drug therapy
Lymphoma, Non-Hodgkin / blood,  drug therapy
Male
Middle Aged
Multiple Myeloma / blood,  drug therapy
Multivariate Analysis
Predictive Value of Tests
Chemical
Reg. No./Substance:
0/Antigens, CD34; 121181-53-1/Filgrastim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia.
Next Document:  Detection of hemizygous deletions in genomic DNA from leukaemia specimens for the diagnosis of patie...